Post-hoc analysis shows that ERLEADA® provides rapid, deep, and durable PSA declines in advanced prostate cancer, with depth and speed of response correlating to improved overall survival
Real-world data demonstrate that, across racial groups, patients prescribed ERLEADA® for non-metastatic castration-resistant prostate cancer stay on therapy
San Francisco, CA (UroToday.com) — The Janssen Pharmaceutical Companies of Johnson & Johnson announced new data demonstrating robust prostate-specific antigen (PSA) response and strong adherence rates in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with ERLEADA® (apalutamide) in the real-world clinical setting. The strong PSA response was also seen in a separate post-hoc analysis that showed a correlation between rapid and deep PSA response and prolonged survival in both metastatic castration-sensitive prostate cancer (mCSPC) and nmCRPC. The post-hoc analysis also supports the use of PSA as a predictive biomarker in the treatment of patients with advanced prostate cancer. These findings were presented during two podium sessions at the virtual American Urological Association Annual Meeting (AUA 2021), September 10-13.